Following the successful launch of our recombinant A1-P1NP antigen (Cat. #8PIN7) last year, Hytest is excited to introduce a new set of monoclonal anti-Procollagen Type I N-Propeptide (P1NP) antibodies. This new release includes five monoclonal antibodies: W188, W509, W510, W543, and W555 (Cat. #4PIA7).

According to the World Health Organization (WHO), osteoporosis has a major impact on quality of life, ranking second only to cardiovascular diseases in terms of global burden. Bone turnover markers (BTMs)—including bone formation markers such as P1NP and osteocalcin, as well as bone resorption markers like beta-CrossLaps (β-CTx)—are gaining increasing attention. The serum P1NP test has been designated by the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) as a reference marker of bone formation. It is used to assess and monitor osteoporosis treatment and to support the diagnosis and follow-up of monostotic Paget’s disease.

All Hytest-recommended antibody pairs (listed below) have been validated on the CLIA platform and meet the limit of detection (LoD) requirement of 5 ng/mL. Among these, the W509 (capture)–W543 (detection) pair demonstrated a strong correlation with the Roche Elecsys Total P1NP assay (r² = 0.9864). These antibody pairs detect both oligomeric and monomeric forms of P1NP in apparently healthy adults, offering high sensitivity. Notably, our prototype assay has revealed substantial levels of the monomeric form in young adults—an observation that may be considered a relatively novel finding.

Recommended pairs:

We also offer recombinant P1NP antigen (Cat. #8PIN7, A1-PINP, rec) for use as a control or calibrator. For more information or to place an order, please contact your regional Sales Team.

Please note: product availability may vary by region.